Adage Capital Partners’s Q32 Bio QTTB Stock Holding History

Adage Capital Partners’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-404,411	Closed	-$18M	–	974
2024 Q3	$18M	Buy	+404,411	New	+$14.9M	0.03%	474

Other funds holding QTTB

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Adage Capital Partners's QTTB Position: Q4 2024 in Review

Adage Capital Partners sold out of Q32 Bio (QTTB) in Q4 2024, closing a stake of 404,411 shares — an estimated $18M sold.

Adage Capital Partners first reported a position in QTTB in Q3 2024 and held it in 1 quarter. The position peaked at $18M in Q3 2024. 92 funds tracked by Wall St. Rank hold QTTB as of Q4 2024.

Adage Capital Partners reported no remaining Q32 Bio position as of Q4 2024 after selling out during the quarter.
Adage Capital Partners sold 404,411 Q32 Bio shares in Q4 2024, an estimated $18M.
Adage Capital Partners first reported a position in Q32 Bio in Q3 2024 and held it in 1 quarter.
Adage Capital Partners's Q32 Bio position peaked at $18M in Q3 2024.
92 funds tracked by Wall St. Rank held Q32 Bio as of Q4 2024.

Based on Adage Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.